InVivo shares plummet as first human trials of spinal cord treatment delayed
This article was originally published in Clinica
InVivo Therapeutics’ stock took a bashing yesterday after the company revealed it was delaying a first-in-human trial of its biopolymer scaffold in acute spinal cord injury (SCI) until the first quarter of 2014. It had said in April that it planned to start the study, testing the safety and performance of the scaffold in five patients, “in the next few months,” after receiving investigational device exemption (IDE) approval from the US FDA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.